Toolgen Inc. and Geneditbio Ltd. struck a strategic cross‑license agreement to jointly advance next‑generation in‑vivo genome‑editing therapeutics. The deal pools IP rights and aims to accelerate delivery, editing specificity and clinical translation for therapeutic gene‑editing programs. Both companies noted the agreement covers platform technologies that enable safer, more efficient in‑vivo editing and is intended to support joint development activities and downstream licensing. The collaboration is positioned to address persistent delivery bottlenecks and regulatory complexity for in‑vivo editing approaches. By sharing proprietary tools, the partners expect to de‑risk preclinical development timelines and broaden opportunities to move candidates into the clinic or into pharma collaborations.